Abstract:
PURPOSE:Due to its specific pharmacokinetic profile, tinzaparin, a low-molecular-weight heparin (LMWH), appears not to be associated with anti-factor Xa accumulation. Our meta-analysis aimed at determining whether long-term curative doses of tinzaparin is a valuable alternative to vitamin K antagonists (VKA) for the treatment of symptomatic venous thromboembolism (VTE), especially in patients with cancer who are at higher risk of recurrence and bleeding. MATERIALS AND METHODS:A systematic literature search identified randomized studies on long-term tinzaparin compared to VKA in patients with VTE. Outcome measures were VTE recurrence, major bleeding, deaths and net clinical benefit combining the three endpoints during the treatment period and at one year. Pooled relative risk was estimated using the logarithm of the relative risk (RR) method based on a fixed-effect model in the overall population and cancer population. RESULTS:Five randomized controlled studies were eligible. No difference between groups in VTE recurrence was found in the overall population (RR=0.85 [0.55; 1.31]). In cancer patients, a non-significant 38% VTE risk reduction in favor of tinzaparin was observed on treatment (RR=0.62 [0.30; 1.31]). The difference was significant at the end of follow-up at one year (RR=0.40 [0.19; 0.82], p<0.01). The incidence of major bleeding in the tinzaparin group was not significantly different from the VKA group in the overall population and cancer patients. CONCLUSIONS:Tinzaparin appears as a valuable option for long-term treatment of patients in whom VKA are contraindicated or difficult to monitor. Tinzaparin may have a more favorable benefit-risk ratio than VKA in patients with cancer and VTE.
journal_name
Thromb Resjournal_title
Thrombosis researchauthors
Laporte S,Bertoletti L,Romera A,Mismetti P,Pérez de Llano LA,Meyer Gdoi
10.1016/j.thromres.2012.08.290subject
Has Abstractpub_date
2012-12-01 00:00:00pages
853-8issue
6eissn
0049-3848issn
1879-2472pii
S0049-3848(12)00662-7journal_volume
130pub_type
杂志文章,meta分析abstract::Normal pregnancy is associated with an increasing state of activation of the haemostatic system. This activation state is excessive in women with placenta-mediated pregnancy complications (PMPCs), including preeclampsia (PE). Platelet activation plays a crucial pathophysiological role in PE. The very early activation ...
journal_title:Thrombosis research
pub_type: 杂志文章
doi:10.1016/S0049-3848(19)30359-7
更新日期:2019-09-01 00:00:00
abstract::Severe rejection crises occurred in 13 out of 20 cadaver kidney recipients; removal of the graft was inevitable in 10 cases. The plasminogen levels were found to be lower (76.5 +/- 2.9%) in the 13 patients with impaired graft acceptance (group B) than in the 7 patients experiencing only moderate rejection (group A, 93...
journal_title:Thrombosis research
pub_type: 杂志文章
doi:10.1016/0049-3848(86)90257-4
更新日期:1986-05-01 00:00:00
abstract:OBJECTIVES:Screening of patients with sepsis for disseminated intravascular coagulation (DIC) has been recommended in several guidelines. However, DIC screening is still not widely accepted as an essential component of sepsis management, partly because of a lack of evidence that DIC screening has an effect on mortality...
journal_title:Thrombosis research
pub_type: 杂志文章,多中心研究
doi:10.1016/j.thromres.2017.11.023
更新日期:2018-01-01 00:00:00
abstract:INTRODUCTION:Circulating levels of fibrinogen are associated with atherosclerosis and predict future coronary heart disease and stroke. Levels of fibrinogen are correlated among family members, suggesting a heritable component. Variants of the beta-fibrinogen gene subunit on 4q28 are associated with fibrinogen levels b...
journal_title:Thrombosis research
pub_type: 杂志文章
doi:10.1016/s0049-3848(03)00288-3
更新日期:2003-04-15 00:00:00
abstract::Polymorphonuclear leukocytes (PMNL) are components of the blood which as such interact extensively with other blood cells, with endothelial cells or with plasma. Here, we consider the interaction between PMNL and platelets which is efficient during adhesion of platelets to PMNL and which can be studied in vitro using ...
journal_title:Thrombosis research
pub_type: 杂志文章
doi:10.1016/s0049-3848(10)80005-2
更新日期:1994-01-01 00:00:00
abstract:INTRODUCTION:In contrast to unfractionated heparin (UFH), use of low-molecular weight heparin (LMWH) during pregnancy has not been reported to be associated with a significant decrease in bone mineral density (BMD). The aim of this study was to investigate whether long-term use of LMWH during pregnancy is associated wi...
journal_title:Thrombosis research
pub_type: 杂志文章
doi:10.1016/j.thromres.2016.05.016
更新日期:2016-07-01 00:00:00
abstract:INTRODUCTION:Medically ill, hospitalized patients are at increased risk for venous thromboembolism (VTE) after discharge. This study aimed to examine thromboprophylaxis patterns, risk factors, and post-discharge outcomes. METHODS:This was a retrospective claims analysis involving administrative claims data and in-pati...
journal_title:Thrombosis research
pub_type: 杂志文章
doi:10.1016/j.thromres.2013.08.013
更新日期:2013-11-01 00:00:00
abstract::COVID-19 has been associated with an increased risk of thrombotic events; however, the reported incidence of deep vein thrombosis varies depending, at least in part, on the severity of the disease. Aim of this prospective, multicenter, observational study was to investigate the incidence of lower limb deep vein thromb...
journal_title:Thrombosis research
pub_type: 杂志文章,多中心研究
doi:10.1016/j.thromres.2020.10.035
更新日期:2021-01-01 00:00:00
abstract::Human platelets synthesize nitric oxide (NO) through an endothelial-type NO synthase (ecNOS) activated also by substances enhancing 3',5'-cyclic adenosine monophosphate (cAMP) concentrations, such as catecholamines, beta-adrenoceptor agonists and adenosine. To verify whether cAMP directly activates ecNOS through the c...
journal_title:Thrombosis research
pub_type: 杂志文章
doi:10.1016/j.thromres.2004.06.036
更新日期:2004-01-01 00:00:00
abstract:INTRODUCTION:Although investigation for JAK2 V617F mutation is recommended in patients presenting with splanchnic venous thrombosis (SVT), no specific clinical advice is given to SVT patients presenting without myeloproliferative neoplasms (MPN) and JAK2 V617F mutation. In MPN-free SVT patients, to investigate the clin...
journal_title:Thrombosis research
pub_type: 杂志文章
doi:10.1016/j.thromres.2013.07.014
更新日期:2013-08-01 00:00:00
abstract::Four monoclonal antibodies have been produced, which are specific for the Ca2+ or Sr2(+)-induced conformation of human factor IX. Certain, but not all, gamma-carboxy-glutamic acid residues in factor IX are involved in the epitope expression together with the conformation stabilized by the adjacent region of Gla-domain...
journal_title:Thrombosis research
pub_type: 杂志文章
doi:10.1016/0049-3848(90)90306-w
更新日期:1990-06-15 00:00:00
abstract::Fluorescein Dextran (FD) was shown to be transported at increased rates through partially denuded endothelial monolayer. Platelet binding to the partially denuded monolayer lowered transport rates to those comparable with intact endothelium. Inhibition of transport by platelet binding was not affected by the addition ...
journal_title:Thrombosis research
pub_type: 杂志文章
doi:10.1016/0049-3848(92)90191-c
更新日期:1992-05-01 00:00:00
abstract::ZK-807834 (also known as CI-1031) is a small molecule that potently and selectively inhibits Factor Xa. Studies in animals have shown that ZK-807834 attenuates thrombosis and thrombus progression after fibrinolysis and exhibits an increased antithrombotic-to-bleeding risk ratio compared with conventional agents. The p...
journal_title:Thrombosis research
pub_type: 杂志文章
doi:10.1016/s0049-3848(02)00024-5
更新日期:2002-02-15 00:00:00
abstract::Coagulation is initiated by tissue factor (TF). Coagulant TF is constitutively expressed by extravascular cells, but there is increasing evidence that TF can also be present within the blood, in particular during pathological conditions. Such TF is exposed on circulating cell-derived vesicles, and its presence has bee...
journal_title:Thrombosis research
pub_type: 杂志文章,评审
doi:10.1016/j.thromres.2012.08.281
更新日期:2012-10-01 00:00:00
abstract::Lysophosphatidic acid (LPA) is a lipid mediator generated by activated platelets and having various effects on numerous cell types. We investigated some effects of 1-oleyl LPA on vascular smooth muscle cells cultured from adult human normal arteries. At micromolar concentrations, LPA induced a mitogenic effect ([3H]-t...
journal_title:Thrombosis research
pub_type: 杂志文章
doi:10.1016/s0049-3848(99)00004-3
更新日期:1999-06-01 00:00:00
abstract::Seven males with atherosclerotic disease received daily 1.6 g of the thromboxane antagonist BM 13.177 in two separate oral dosages over a period of four days. The drug significantly reduced elevated plasma levels of thromboxane B2, beta-thromboglobulin and platelet factor 4, whereas thromboxane B2 generation was only ...
journal_title:Thrombosis research
pub_type: 杂志文章
doi:10.1016/0049-3848(84)90229-9
更新日期:1984-08-15 00:00:00
abstract::Activation of human platelets by PAF was augmented by C-reactive protein, an acute phase plasma protein. The concentration of PAF required for irreversible activation (secondary aggregation of platelet and release of serotonin) was decreased to 1/10 in the presence of C-reactive protein (CRP). The presence of CRP stim...
journal_title:Thrombosis research
pub_type: 杂志文章
doi:10.1016/0049-3848(86)90361-0
更新日期:1986-03-01 00:00:00
abstract::There is a close interrelation between cancer and haemostasis, which is characterized by changes in the haemostatic system, mostly an activation of coagulation in cancer patients. Venous thromboembolism (VTE) is a frequent complication of cancer and in particular of anticancer therapy and is associated with significan...
journal_title:Thrombosis research
pub_type: 杂志文章,评审
doi:10.1016/S0049-3848(10)70005-0
更新日期:2010-04-01 00:00:00
abstract::Venous thromboembolism (VTE) is a preventable disease, yet it is one of the leading causes of death among patients with cancer. Improving risk stratification mechanisms will allow us to personalize thrombo-prophylaxis strategies. We sought to evaluate Collagen and Thrombin Activated Platelets (COAT-platelets) as well ...
journal_title:Thrombosis research
pub_type: 杂志文章
doi:10.1016/j.thromres.2015.10.004
更新日期:2015-12-01 00:00:00
abstract:INTRODUCTION:Warfarin is the most widely used oral anticoagulant. It has been suggested that anticoagulation effect of warfarin is significantly associated with the polymorphism of certain genes, including Cytochrome P450 complex subunit 2C9 (CYP2C9), Vitamin K Epoxide Reductase Complex Subunit 1 (VKORC1), Gamma-Glutam...
journal_title:Thrombosis research
pub_type: 杂志文章,meta分析,评审
doi:10.1016/j.thromres.2009.10.017
更新日期:2010-04-01 00:00:00
abstract::The need for anticoagulation in dialysis patients is common and the incidence of venous thromboembolism (VTE) and atrial fibrillation in this population is high. While direct data are lacking on the management of anticoagulation in dialysis patients, careful weighing of risks and benefits on the basis of evidence from...
journal_title:Thrombosis research
pub_type: 杂志文章,实务指引
doi:10.1016/j.thromres.2005.03.031
更新日期:2006-01-01 00:00:00
abstract::We characterized a platelet specific alloantigen (Yukb). In immunoblotting, anti-Yukb antibody was found to react with both 110 kDa and 96 kDa bands under nonreducing condition. Immunoblotting followed by separation by two-dimensional electrophoresis (isoelectric focusing/SDS-PAGE) showed that the 96 kDa band had a pI...
journal_title:Thrombosis research
pub_type: 杂志文章
doi:10.1016/0049-3848(92)90136-x
更新日期:1992-07-15 00:00:00
abstract::Studies with animal models implicate the plasma proteases factor XIIa (FXIIa) and α-kallikrein in arterial and venous thrombosis. As congenital deficiencies of factor XII (FXII) or prekallikrein (PK), the zymogens of FXIIa and α-kallikrein respectively, do not cause bleeding disorders, inhibition of these enzymes may ...
journal_title:Thrombosis research
pub_type: 杂志文章
doi:10.1016/j.thromres.2016.02.020
更新日期:2016-04-01 00:00:00
abstract:INTRODUCTION:Post-thrombotic syndrome (PTS) is a chronic sequel of deep vein thrombosis (DVT). The clot structure and fibrinolytic potential in PTS is currently unknown. OBJECTIVE:To assess the fibrinolytic potential and clot structure in patients with PTS. MATERIALS AND METHODS:Patients with a history of DVT were in...
journal_title:Thrombosis research
pub_type: 杂志文章
doi:10.1016/j.thromres.2015.11.013
更新日期:2016-01-01 00:00:00
abstract::Heparin-induced thrombocytopenia (HIT) is a transient hypercoagulability state initiated, paradoxically, by the anticoagulant, heparin. It is characterized by antibody-induced activation of platelets, leading to thrombin generation. Many patients with HIT develop thrombosis; even when heparin is stopped because of "is...
journal_title:Thrombosis research
pub_type: 杂志文章,评审
doi:10.1016/s0049-3848(03)00336-0
更新日期:2003-05-01 00:00:00
abstract::beta-Factor XIIa (beta-XIIa, Mr approximately 30,000) was isolated from human plasma by a procedure which utilized, as an initial step, the adsorption of Factor XII to celite. Activation of Factor XII and subsequent release of beta-XIIa was brought about by the proteolytic action of co-adsorbed kallikrein. Two success...
journal_title:Thrombosis research
pub_type: 杂志文章
doi:10.1016/0049-3848(82)90231-6
更新日期:1982-02-15 00:00:00
abstract::Evidence is presented for in vitro high affinity binding of serotonin (5-HT) by beta-thromboglobulin (beta TG) and platelet factor 4 (PF4) from human blood. Results include: 1) identification by radioimmunoassay of PF4 in specifically bound material obtained by 5-HT affinity chromatography of human platelet extracts; ...
journal_title:Thrombosis research
pub_type: 杂志文章
doi:10.1016/0049-3848(83)90044-0
更新日期:1983-02-01 00:00:00
abstract:INTRODUCTION:Systemic embolism is the most serious complication of cardioversion of atrial fibrillation (AF) and the immediate post-cardioversion period is associated with increased risk for thrombus formation. For this reason, treatment with vitamin K antagonist (VKA) is recommended for patients with AF. No informatio...
journal_title:Thrombosis research
pub_type: 杂志文章,多中心研究
doi:10.1016/j.thromres.2011.08.031
更新日期:2012-05-01 00:00:00
abstract::Flavocetin-A is a strong platelet aggregation inhibitor isolated from the venom of Trimeresurus flavoviridis. It binds specifically to platelet glycoprotein Ib with high affinity and inhibits von Willebrand factor-dependent platelet aggregation. The apparent molecular weight of flavocetin-A is 149 kDa. It consists of ...
journal_title:Thrombosis research
pub_type: 杂志文章
doi:10.1016/s0049-3848(00)00234-6
更新日期:2000-08-01 00:00:00
abstract::There are some issues in the current factor (F)VIII replacement therapy for severe hemophilia A. One is mental and physical burden for the multiple intravenous infusions, and the other is difficulty in the hemostatic treatment for the patients with FVIII inhibitor. The development of novel drug with fully hemostatic e...
journal_title:Thrombosis research
pub_type: 杂志文章,评审
doi:10.1016/S0049-3848(16)30361-9
更新日期:2016-05-01 00:00:00